Immune Response to Cytomegalovirus
Measurement of Cytomegalovirus (CMV)-Specific T Lymphocytes in CMV-Seropositive Normal Volunteers.
2 other identifiers
observational
20
1 country
1
Brief Summary
This study will evaluate immune responses against cytomegalovirus (CMV). About 80 percent of adults have been exposed to this virus. CMV typically remains dormant (inactive) in the body, causing no problems. In people with immune suppression, however, the virus can become reactivated and cause life-threatening pneumonia. The knowledge gained from this study may be useful in developing ways to improve immune responses to CMV in stem cell transplant recipients. Healthy normal volunteers between 18 and 65 years of age who have been exposed to cytomegalovirus are eligible for this study. Candidates will be screened with a medical history and blood tests. Those enrolled will provide a 30-milliliter (6-tablespoon) blood sample once a week for 4 weeks and a final sample 2 months later. The blood will be used to design a test to detect immune responses against CMV and determine the differences in these responses among healthy individuals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Apr 2002
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2002
CompletedFirst Submitted
Initial submission to the registry
April 27, 2002
CompletedFirst Posted
Study publicly available on registry
April 29, 2002
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2003
CompletedMarch 4, 2008
April 1, 2003
April 27, 2002
March 3, 2008
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- Age 18-65
- CMV seropositive
- Informed consent given
You may not qualify if:
- CMV seronegative
- Abnormal blood counts (hemoglobin less than 12 g/dl, platelets less than 150,000/ul, absolute neutrophil count less than 1,500/ul, absolute lymphocyte count less than 1,000/ul)
- Known history of heart, lung, kidney, liver, or bleeding disorder
- Diagnosis of HIV infection
- Diagnosis or suspicion of immunodeficiency state
- History of intravenous drug use
- Currently pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Sponsor Type
- NIH
Study Record Dates
First Submitted
April 27, 2002
First Posted
April 29, 2002
Study Start
April 1, 2002
Study Completion
April 1, 2003
Last Updated
March 4, 2008
Record last verified: 2003-04